Journals / art / 2015 / Cilt: 30 - Sayı: 3

Evaluation of the Prevalence of Rheumatoid Factor in Five Regions of Cameroon

Journal
art
Pages
226–230
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies are needed to bring more insight on the prevalence of RF in Cameroon.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to assess the prevalence of rheumatoid factor (RF) of immunoglobulin M nature in the Cameroonian population and the influence of demographic factors on its production.
📊
Key Findings & Data:Patients and methods: A total of 369 subjects (125 males and 244 females; mean age 42.36±15.73 years; range 15-88 years) were tested from five regions of Cameroon (Center, East, Far North, Littoral and West) between July 2012 and December 2012.
💡
Conclusion & Impact:Further studies are needed to bring more insight on the prevalence of RF in Cameroon.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to assess the prevalence of rheumatoid factor (RF) of immunoglobulin M nature in the Cameroonian population and the influence of demographic factors on its production. Patients and methods: A total of 369 subjects (125 males and 244 females; mean age 42.36±15.73 years; range 15-88 years) were tested from five regions of Cameroon (Center, East, Far North, Littoral and West) between July 2012 and December 2012. Whole blood was collected from each participant and the serum was used for immunoglobulin M RF assay using the RF-IMMESCO test (agglutination technique). Results: The prevalence of RF in the whole population was 5.4%, with a female to male ratio of 2.4. RF was present in all age groups, but especially in participants of 30 to 60 years of age. The Center region had the highest prevalence (7.5%), while the West region had the lowest prevalence (2.2%). However, there was no significant difference between studied regions (p>0.05). Of the 369 participants tested, 257 (69.6%) complained of having suffered joint pain at one time or another while 112 did not complain of joint pain. The prevalence of RF was 6.22% in the former group and 3.57% in the latter. Among those 50 to 70 years of age, nearly 90% had at least one painful joint. Conclusion: The presence of RF in the study population may lead to joint diseases, which are more common disabling diseases among the inhabitants of Cameroon. Further studies are needed to bring more insight on the prevalence of RF in Cameroon.

🔖

Cite This Article

ATABONKENG, E. P., ADIOGO, D., EMMANUEL, E. M., HERVÉ, O. F., MANGA, A. O., OKOMO, M. C. A. (2015). Evaluation of the Prevalence of Rheumatoid Factor in Five Regions of Cameroon. art, Cilt: 30 - Sayı: 3, 226–230. https://ajindex.com/articles/351776

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Bonnotte B. Pathogenic mechanisms of autoimmune diseases. Rev Med Interne 2010;31:292-5
  2. Sany J. La polyarthrite rhumatoïde de l’adulte. John Libbey Eurotext Ed 2003. p. 298
  3. Preud’homme JL, Clot J, Pasquali Jl, Youinou P, Saraux A. Autoimmunité et Autoanticorps. Cahier de Formation 1999. p. 1-24
  4. Kereveur A, Myara I. Physiopathologie des immunscomplexes circulants. Eurobiologiste 1995;29:51-8
  5. Morel J, Combe B. How to predict prognosis in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19:137-46
  6. Dayer E, Consilia S, Buchard PA, Suva S. Ac anti-peptide cyclique citrulliné (CCP) et Polyarthrite rhumatoïde. Caduceus Express 2004;6. Available from: https://web2.hopitalvs.ch/fr/ichv/ DocumentationDoc/2004_02_Anti%20CCP_ED_F. pdf 7. Skare TL, Silva BG, Gomes D, Gomes F, Rumor C, Giacomini G. Rheumatoid factor and tobacco exposure. Braz Arch Biol Technol 2002;45:203-7
  7. Jeandel P, Chouc PY, Laroche R. Rhumatologie en Afrique Noire: Certitudes, Perspectives et Inconnues. Médecine d’Afrique Noire 1991;38:53-61
  8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
  9. Nielsen SF, Bojesen SE, Schnohr P, Nordestgaard BG. Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ 2012;345:5244
  10. Viatte S, Flynn E, Lunt M, Barnes J, Singwe-Ngandeu M, Bas S, et al. Investigation of Caucasian rheumatoid arthritis susceptibility loci in African patients with the same disease. Arthritis Res Ther 2012;14:239. 12.Devouassoux G. Physiologie des Hypersensibilités de type III-Immunologie et Mécanismes Immunopathologiques. CHLS & INSERM 2010:23:3-5. 13.Klemmer N, Vittecoq O. Polyarthrite rhumatoïde et facteurs environnementaux. La Lettre du Rhumatologue 2004;307:4
  11. Andrade F, Darrah E, Rosen A. Autoantibiodies in rheumatoid arthritis. In: Firestein GS, Budd RC, Gabriel SE, editors. Kelley's Textbook of Rheumatology. Chap 56. 9th ed. Philadelphia: Saunders Elsevier; 2012. p. 3-7
  12. Juby AG, Davis P. Prevalence and disease associations of certain autoantibodies in elderly patients. Clin Invest Med 1998;21:4-11
  13. Önen F, Türkay C, Meydan A, Dökmeta HS, Sümer H, Hocao¤lu L, et al. Prevalence of Rheumatoid Factor (RF) and Anti-native-DNA Antibodies (anti-n DNA) in Different Age Subpopulations. Tr. J. of Medical Sciences 1998;28:85-8.